Icon Plc (NASDAQ:ICLR) – Research analysts at First Analysis upped their Q1 2018 earnings per share estimates for Icon in a research note issued on Friday, Zacks Investment Research reports. First Analysis analyst T. Van. Fleet now anticipates that the medical research company will earn $1.37 per share for the quarter, up from their prior estimate of $1.36. First Analysis also issued estimates for Icon’s Q2 2018 earnings at $1.53 EPS, Q3 2018 earnings at $1.53 EPS, Q4 2018 earnings at $1.54 EPS, FY2018 earnings at $5.97 EPS and FY2019 earnings at $6.53 EPS.
A number of other research firms have also recently weighed in on ICLR. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub raised shares of Icon from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. KeyCorp reissued a “buy” rating and issued a $130.00 price objective on shares of Icon in a research report on Thursday, January 11th. Mizuho set a $109.00 price objective on shares of Icon and gave the company a “hold” rating in a research report on Wednesday, January 24th. Finally, SunTrust Banks reissued a “buy” rating and issued a $133.00 price objective on shares of Icon in a research report on Monday, January 22nd. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $126.00.
Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, February 15th. The medical research company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.02. The company had revenue of $455.10 million during the quarter, compared to analysts’ expectations of $455.66 million. Icon had a net margin of 16.01% and a return on equity of 27.55%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.33 EPS.
Several hedge funds have recently modified their holdings of ICLR. Schwab Charles Investment Management Inc. lifted its position in shares of Icon by 39.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 16,713 shares of the medical research company’s stock worth $1,635,000 after purchasing an additional 4,692 shares during the last quarter. Northern Trust Corp lifted its position in shares of Icon by 5.5% during the second quarter. Northern Trust Corp now owns 249,247 shares of the medical research company’s stock worth $24,373,000 after purchasing an additional 13,099 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Icon by 19.8% during the second quarter. Vanguard Group Inc. now owns 14,545 shares of the medical research company’s stock worth $1,422,000 after purchasing an additional 2,400 shares during the last quarter. Gotham Asset Management LLC acquired a new stake in Icon during the second quarter worth about $392,000. Finally, Cubist Systematic Strategies LLC raised its stake in Icon by 11.0% during the second quarter. Cubist Systematic Strategies LLC now owns 4,844 shares of the medical research company’s stock worth $474,000 after acquiring an additional 481 shares during the period. 90.50% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://stocknewstimes.com/2018/03/14/q1-2018-eps-estimates-for-icon-plc-iclr-increased-by-first-analysis.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.